{"id":"NCT02797080","sponsor":"Amgen","briefTitle":"Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia","officialTitle":"Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-28","primaryCompletion":"2017-03-31","completion":"2017-03-31","firstPosted":"2016-06-13","resultsPosted":"2018-05-01","lastUpdate":"2024-12-10"},"enrollment":38,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Friedreich's Ataxia"],"interventions":[{"type":"DRUG","name":"interferon γ-1b","otherNames":["ACTIMMUNE®"]}],"arms":[{"label":"interferon γ-1b","type":"EXPERIMENTAL"}],"summary":"The purpose of this long term extension study is to evaluate the long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia (FA).","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs","timeFrame":"Baseline/Day 1 (Week 28 Follow-Up Visit for Study HZNP-ACT-302 ([NCT02593773]) through end of study; mean (SD) duration of treatment was 99.2 (58.48) days.","effectByArm":[{"arm":"Interferon γ-1b","deltaMin":21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":38},"commonTop":["Headache","Influenza","Fatigue","Nasopharyngitis","Upper respiratory tract infection"]}}